Scientific deep-dive

Switching Between GLP-1 Medications: The Complete Protocol Guide

Can you switch from semaglutide to tirzepatide, Ozempic to Wegovy, Wegovy injection to tablets, or to oral Foundayo? Every switching scenario with label-defined switching rules, washout timing, re-titration, and what to expect.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
11 min read·12 citations

Switching between GLP-1 medications is increasingly common: patients plateau on semaglutide and want to try tirzepatide, commercial insurance starts covering Zepbound so patients move off Wegovy, a compounded vial supply problem pushes patients back to brand-name pens, or the new Foundayo (oral orforglipron) becomes an option for patients who hate injections. Each switching scenario has a different protocol and a different washout period. This guide walks through every common switch, separating the few switches the FDA labels actually spell out (semaglutide injection ↔ semaglutide tablets, and Rybelsus ↔ Ozempic tablets) from the cross-molecule switches where no label gives a dose conversion. Any actual switching decision belongs between you and your prescriber — this is an educational explainer, not a dose recommendation.

Can you switch between GLP-1s?

Yes, switching is clinically routine and happens for several legitimate reasons [5]:

  • Plateau or non-response. A patient on semaglutide 2.4 mg at maintenance who has truly stopped losing weight after week 40 may benefit from switching to tirzepatide, which produced larger mean weight loss in SURMOUNT-1 than STEP-1 reported for semaglutide [1, 2].
  • Insurance coverage changes. The most common real-world reason. An employer adds Zepbound to the formulary, or Wegovy goes off, or a patient moves to a plan with different anti-obesity drug coverage, and they need to switch drugs mid-therapy.
  • Side effect intolerance. Some patients tolerate tirzepatide's GI side-effect profile better than semaglutide, or vice versa. Switching is the clean way to test the other option.
  • Supply shortages. Compounded supply can become unreliable when 503A pharmacies cycle on and off the FDA shortage list, pushing patients onto brand-name pens. Brand-name supply has also had intermittent shortages.
  • Price changes. Foundayo launched at a self-pay price starting at $149/month for the lowest dose (higher doses cost more) [10], which gives some patients on compounded vials a brand-name oral alternative.

General switching principles

Across every scenario, a few common rules apply [3, 4, 5, 6]:

  1. Don't combine GLP-1s. The Wegovy, Zepbound, and Foundayo prescribing information all state that using the drug together with another GLP-1 receptor agonist is not recommended [3, 4, 6]. When switching, the old drug stops and the new drug starts — no overlap.
  2. Time the switch to your next scheduled injection. Semaglutide has an elimination half-life of about 1 week and tirzepatide about 5 days [4, 9]. The cleanest switch happens at the natural weekly injection point — skip the next dose of the old drug and take the first dose of the new drug in its place. That one-week gap is exactly what the semaglutide labels specify when moving from a weekly injection to a daily tablet [3, 7].
  3. Restart the titration ramp on a new molecule. The FDA-approved titration schedules exist to let the GI tract adapt. The Wegovy, Zepbound, and Foundayo labels each give one starting dose for all patients (0.25 mg for Wegovy injection; 2.5 mg for Zepbound; 0.8 mg for Foundayo) and contain no instructions for switching in from a different GLP-1 molecule [3, 4, 6]. So when the molecule changes, prescribers generally restart at the new drug's starting dose and ramp up on its standard schedule. Skipping the ramp raises the risk of severe GI side effects.
  4. Do not expect the titration period to be “wasted time.” Patients switching from maintenance-dose sema to tirz assume they'll just continue losing weight on the new drug's starter dose. In practice, during the 16-20 weeks it takes to re-titrate, weight loss slows significantly — you may even see a small regain during the early ramp weeks. This is expected and the curve usually catches up once maintenance is reached on the new drug.

Scenario 1: Semaglutide → Tirzepatide (the most common switch)

This is the most-searched switching scenario. Typical patient profile: on Wegovy 2.4 mg or Ozempic for weight loss, plateaued or wants larger effect, insurance now covers Zepbound.

Protocol

  1. Finalize with your prescriber. They write a new tirzepatide prescription and cancel the remaining semaglutide refills (or advise you to discard remaining doses).
  2. Take your last semaglutide dose on your regular injection day. This is day 0.
  3. One week later (day 7 — your next scheduled injection day), start tirzepatide 2.5 mg. This is the FDA-approved starter dose for Zepbound [4]. Do not start at a higher dose even if you were on maintenance semaglutide — the tirzepatide titration schedule exists for GI tolerance and skipping it produces severe nausea.
  4. Follow the standard tirzepatide titration ramp: 2.5 mg for 4 weeks, then increases in 2.5 mg steps after at least 4 weeks on each dose. The label's maintenance options for weight reduction are 5 mg, 10 mg, or 15 mg weekly, with 15 mg the maximum [4]; your prescriber picks based on response and tolerability.

What to expect

  • Weeks 1-4 on 2.5 mg: Mild GI symptoms are common. Appetite suppression may feel weaker than you remember on maintenance semaglutide because you're back at the starting dose.
  • Weeks 5-16 (escalation): Appetite suppression typically strengthens as the dose climbs. There is no validated point at which a given tirzepatide dose “equals” your old semaglutide dose (see below) — judge progress by your own weight trend and side effects, not by a conversion chart.
  • Week 20 onward (10-15 mg maintenance, if reached): In the SURMOUNT-5 head-to-head trial, maximum-tolerated tirzepatide produced a mean −20.2% weight change at 72 weeks vs −13.7% with maximum-tolerated semaglutide [12] — but that was in people starting both drugs fresh, not switching mid-course.

Scenario 2: Tirzepatide → Semaglutide

Less common than sema → tirz, but happens for insurance reasons or when tirzepatide side effects are intolerable and the patient wants to try semaglutide.

Protocol

  1. Take your last tirzepatide dose on your regular day.
  2. One week later, start semaglutide 0.25 mg. FDA-approved starter dose for Wegovy and Ozempic injection [3, 9]. (If the destination is Wegovy tablets instead, the starting dose is 1.5 mg daily, escalated every 30 days to 25 mg [3].)
  3. Standard semaglutide titration ramp: 0.25 mg for 4 weeks → 0.5 mg → 1 mg → 1.7 mg, then maintenance. For Wegovy weight reduction, maintenance is 1.7 mg or 2.4 mg (recommended); patients who tolerate 2.4 mg for at least 4 weeks may go up to a maximum of 7.2 mg weekly if more weight reduction is clinically indicated [3]. Ozempic's glycemic-control maintenance doses are 0.5, 1, or 2 mg [9].

Expect weight loss to be smaller on average than on tirzepatide: in SURMOUNT-5, the only head-to-head obesity trial, semaglutide produced −13.7% vs −20.2% for tirzepatide at 72 weeks [12]. GI side effects were common and mostly mild to moderate with both drugs.

Scenario 3: Ozempic → Wegovy (same drug, different label)

Ozempic and Wegovy are both semaglutide manufactured by Novo Nordisk — same molecule, same manufacturer, different FDA labels and different maximum doses [3, 9]. Ozempic injection's diabetes label caps at 2 mg weekly; Wegovy's weight-reduction label recommends 2.4 mg and allows up to 7.2 mg weekly in adults who tolerate 2.4 mg [3]. The switch is primarily about insurance (Ozempic often covered for T2D patients, Wegovy for obesity).

Protocol

  1. Wegovy dose strengths. Per the Wegovy label Section 3 [3], single-dose pens come in 0.25, 0.5, 1, 1.7, 2.4, and 7.2 mg (the 7.2 mg pen is branded WEGOVY HD), plus a multi-dose FlexTouch pen that delivers 2.4 mg doses — there is no “Wegovy 2 mg” strength. If you are already at Ozempic 2 mg, your prescriber will choose between Wegovy 1.7 mg and 2.4 mg based on tolerability and clinical goals.
  2. If on a lower Ozempic dose (0.5 mg, 1 mg), many prescribers continue at the matching Wegovy strength because the molecule is identical. Note that the Wegovy label itself contains no Ozempic-to-Wegovy switching instructions [3], so this is clinical judgment rather than a label-defined rule.

This is usually the simplest cross-brand switch: same molecule, same weekly schedule, mostly a pharmacy/insurance change.

Scenario 4: Semaglutide injection ↔ semaglutide tablets (the switches the labels spell out)

Semaglutide now comes as three oral products — Wegovy tablets (weight management), Rybelsus, and Ozempic tablets (type 2 diabetes) — and these are the only GLP-1 switches where the FDA labels give explicit dose-for-dose instructions [3, 7]:

  • Wegovy injection → Wegovy tablets. Adults on Wegovy 2.4 mg injection for weight reduction or cardiovascular risk reduction may switch to Wegovy 25 mg tablets, starting one week after the last injection [3].
  • Wegovy tablets → Wegovy injection. The day after the last 25 mg tablet, start Wegovy 2.4 mg injection once weekly. Patients who did not tolerate the 25 mg tablet can be switched to the 1.7 mg injection instead [3].
  • Ozempic injection → Rybelsus or Ozempic tablets. Only patients on Ozempic 0.5 mg injection are covered: one week after the last injection, start Rybelsus 7 mg or 14 mg, or Ozempic tablets 4 mg or 9 mg, once daily [7].
  • Rybelsus ↔ Ozempic tablets. Not allowed during the first 30 days (initiation phase). After that, start the other tablet the day after stopping the first, using the label's mapping [7]:
Rybelsus (once daily)Ozempic tablets (once daily)
7 mg4 mg
14 mg9 mg

Oral semaglutide doses are numerically much larger than injected doses because only about 0.4% to 2% of a tablet dose is absorbed [7], so the milligram numbers cannot be compared across routes. Only use the specific pairings above, and only for the products named. All semaglutide tablets must be taken on an empty stomach with up to 4 ounces of water, at least 30 minutes before food, drinks, or other oral medications [3, 7].

Scenario 5: Wegovy → Zepbound (or vice versa)

This is a different-molecule switch (semaglutide to tirzepatide), so treat it like Scenario 1 — last semaglutide dose, skip one week, start tirzepatide at 2.5 mg and ramp up [4]. Going the other way (Zepbound → Wegovy) follows Scenario 2. Formulary changes that prefer one brand over the other are the most common trigger.

Scenario 6: Brand-name → Compounded

Patients who can't afford brand-name pens often move to compounded vials through a telehealth provider. The same-molecule rule applies:

  • Wegovy/Ozempic → compounded semaglutide: Same molecule, so prescribers usually keep the same mg dose — but compounded products are not FDA-approved and have no label to define the switch. The main operational change is the injection format (pen → vial with insulin syringe), which requires learning the unit-vs-mg conversion (see our unit converter).
  • Zepbound/Mounjaro → compounded tirzepatide: Same molecule; prescribers usually keep the same mg dose. Same operational change to the vial-and-syringe format.

The clinical switch is usually simple because the active drug is the same. The technical switch (learning to draw a dose from a vial with an insulin syringe) is the main new thing to adapt to. See our pen vs compounded vial deep-dive for the full operational comparison.

Scenario 7: Compounded → Brand-name

Patients switching back to brand-name pens (usually because they got insurance coverage, or because of quality concerns about a specific compounding pharmacy). Same logic as the reverse: same molecule, usually the same mg dose (confirm with your prescriber, since compounded concentrations vary), new delivery format.

Scenario 8: Injectable → Foundayo (oral orforglipron)

Foundayo was FDA-approved on April 1, 2026 [10] and is a different molecule than semaglutide or tirzepatide — it's a non-peptide small-molecule GLP-1 agonist. Patients switching from injectable sema or tirz to oral Foundayo are making both a drug change and a delivery-format change.

What the label says

  1. The Foundayo label has no instructions for switching from another GLP-1. It gives one starting dose for everyone: 0.8 mg orally once daily [6].
  2. The label ramp is 0.8 mg → 2.5 mg → 5.5 mg, then optionally 9 mg → 14.5 mg → 17.2 mg (maximum), with at least 30 days on each dose before increasing [6].
  3. It can be taken any time of day, with or without food [6]. If you use oral hormonal contraceptives, the label advises switching to a non-oral method or adding a barrier method for 30 days after starting and after each dose increase [6].

What the switching trial showed

ATTAIN-MAINTAIN, a 52-week randomized trial published in 2026, moved people who had finished the SURMOUNT-5 injectable trial (tirzepatide, n=205; semaglutide, n=171) onto once-daily orforglipron or placebo [8]. The first dose was given ideally within 14 days of the last injection, and participants started directly at a mid-range dose of the investigational formulation (12 mg) rather than the lowest dose, then escalated every 4 weeks toward 36 mg. GI side effects in the first 4 weeks occurred in about 10% of participants, and none needed a dose reduction in that window. Among participants who had reached a weight plateau, orforglipron kept about 75% (ex-tirzepatide) and 79% (ex-semaglutide) of their prior weight reduction at week 52, vs about 49% and 38% on placebo [8].

Two caveats: the trial used an investigational formulation whose milligram doses differ from the commercial Foundayo strengths, and it had no arm that stayed on the injectable [8]. So it supports orforglipron as a way to hold on to most of an injectable's weight loss — not a label-sanctioned shortcut past the 0.8 mg starting dose. Expect the peak effect of Foundayo itself to be smaller than injectable tirzepatide (−11.1% at 17.2 mg in the label's 72-week Trial 1 vs −20.9% at 15 mg in SURMOUNT-1; cross-trial comparison) [2, 6]. See our Foundayo approval deep-dive for the full trial data.

Magnitude comparison

Trial-endpoint total body-weight reduction at the FDA-approved maintenance dose of each GLP-1 — the magnitude frame patients should anchor any switching decision against. Cross-trial comparison, not head-to-head; populations and durations differ.[1][2][6]

  • Foundayo — orforglipron 17.2 mg oral daily (ATTAIN-1, 72 wk)11.1 % TBWL
    oral pill; smallest magnitude of the three; self-pay from $149/month at the lowest dose
  • Wegovy — semaglutide 2.4 mg weekly (STEP-1, 68 wk)14.9 % TBWL
  • Zepbound — tirzepatide 15 mg weekly (SURMOUNT-1, 72 wk)20.9 % TBWL
    largest magnitude; drives most semaglutide -> tirzepatide switches
Trial-endpoint total body-weight reduction at the FDA-approved maintenance dose of each GLP-1 — the magnitude frame patients should anchor any switching decision against. Cross-trial comparison, not head-to-head; populations and durations differ.

For the specific Foundayo ↔ Zepbound switching question — including the side-by-side §2 dose ranges of both labels, the cross-trial efficacy comparison (ATTAIN-1 −11.1% at 17.2 mg vs SURMOUNT-1 −20.9% at 15 mg, 72 weeks each), the practical re-titration pattern when switching, and the oral-contraceptive label-asymmetry that affects patients of reproductive potential — see our companion Foundayo ↔ Zepbound switch dose-equivalence guide. There is no FDA-approved equivalence table; switching between these two specific drugs is a prescriber decision anchored to the receiving drug's §2 missed-dose rule.

Why there is no semaglutide-to-tirzepatide dose equivalence table

There is no formal FDA-approved dose equivalence between semaglutide and tirzepatide. The two molecules target different receptors (semaglutide is a pure GLP-1 agonist; tirzepatide is a dual GIP/GLP-1 agonist), the dose-response curves are not parallel, and in SURPASS-2, the head-to-head trial in type 2 diabetes, even the lowestmaintenance tirzepatide dose (5 mg) produced greater HbA1c and weight reduction than semaglutide 1 mg [11]. That finding rules out any clean “1 mg sema = 5 mg tirz” mapping. SURMOUNT-5, the head-to-head obesity trial, compared each drug at its maximum tolerated dose and likewise offers no dose-for-dose conversion [12]. The only label-defined dose mappings in this class are within semaglutide itself (Scenario 4) [3, 7].

Practically, this means a prescriber switching a patient from semaglutide to tirzepatide will restart at the FDA-approved tirzepatide starter dose (2.5 mg) and titrate on the standard 4-week schedule, regardless of what semaglutide dose the patient was on. The reverse switch (tirz → sema) restarts at semaglutide 0.25 mg with the standard ramp. Trying to “match” the prior dose level on the new molecule is not supported by any head-to-head randomized data and is not how the labels are written [3, 4].

Common switching mistakes to avoid

  1. Combining two GLP-1s. Both drugs' FDA labels recommend against this [3, 4]. Do not take your last semaglutide dose and the first tirzepatide dose on the same day. Skip the next scheduled dose of the old drug.
  2. Skipping the new drug's titration ramp. “I was at maintenance on the old drug so I'll start the new one at maintenance too” — this produces severe nausea and frequently leads to discontinuation. The titration schedule exists because the GI tract needs to re-adapt to the new molecule, not because the nervous system needs to re-adapt to GLP-1 signaling in general.
  3. Not understanding the weight-loss pause during re-titration. The 16-20 week ramp on the new drug usually produces slower weight loss or even minor regain before the curve catches up. This is not a failure — it's the shape of the curve. See our onset guide for week-by-week expectations.
  4. Switching drugs when the real problem is technique. Many patients who think they've plateaued have actually developed lipohypertrophy at a favorite injection site, or are miscalculating the unit-to-mg conversion on a compounded vial. Fix those first. See our plateau guide.

Frequently Asked Questions

Yes, but most clinicians stop one drug before starting the other rather than overlapping. There is no FDA-approved cross-titration protocol. A common approach: take the last Wegovy dose, wait 7 days (one full dosing interval), then start Zepbound at the standard 2.5mg starter dose and titrate up per the Zepbound label. Discuss the specific transition plan with your prescriber before changing.
Common reasons: insurance coverage changed, side effects (often GI) on the current drug, weight loss has plateaued, supply/availability issues, cost, or the new drug has stronger efficacy data for your situation. SURMOUNT-5 (head-to-head tirzepatide vs semaglutide) showed tirzepatide produced greater weight loss on average, which has driven many switches from Wegovy to Zepbound.
When you change molecules (for example semaglutide to tirzepatide), generally yes. The Wegovy, Zepbound, and Foundayo labels each give a single starting dose and contain no instructions for switching in from a different GLP-1, so prescribers typically restart the new drug's titration. The exception is switching within semaglutide: the labels let patients on Wegovy 2.4 mg injection move straight to Wegovy 25 mg tablets (and back to 2.4 mg injection), and patients on Ozempic 0.5 mg injection move to Rybelsus 7 or 14 mg or Ozempic tablets 4 or 9 mg. The ATTAIN-MAINTAIN trial also started orforglipron above its lowest dose after injectable therapy, but that is trial data, not label guidance.
Probably not significantly in a 1-2 week gap. The Wegovy label puts semaglutide's half-life at about 1 week and says it stays in the circulation for about 5 to 7 weeks after the last 2.4 mg or 7.2 mg dose, so the old drug is still active while the new one starts. Most patients notice no meaningful change in a brief switching window. Longer gaps (4+ weeks) start to allow measurable regain.
Yes. The active ingredient is the same. The main differences are concentration (compounded vials vs fixed-dose pens), the dispensing format, and the lack of an FDA-approved label for the compounded preparation. Match the new dose to the equivalent on the new format — our GLP-1 unit converter handles the math. Always confirm with your prescriber before switching formats.

References

  1. 1.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
  2. 2.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  3. 3.Novo Nordisk Inc. WEGOVY (semaglutide) injection and WEGOVY (semaglutide) tablets — US Prescribing Information (Sections 2.2–2.5 and 3: dosing, 7.2 mg maximum, injection↔tablet switching). DailyMed (NLM), SetID ee06186f-2aa3-4990-a760-757579d8f77b. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  4. 4.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information. DailyMed (NLM), SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  5. 5.Wharton S, Davies M, Dicker D, Lingvay I, Mosenzon O, Rubino DM, Pedersen SD. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine. 2022. PMID: 34775881.
  6. 6.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets — US Prescribing Information (Section 2 dosing; Section 14, Trial 1: −11.1% body weight at 17.2 mg, 72 weeks). DailyMed (NLM), SetID 8ac446c5-feba-474f-a103-23facb9b5c62. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  7. 7.Novo Nordisk Inc. RYBELSUS (semaglutide) tablets and OZEMPIC (semaglutide) tablets — US Prescribing Information (Sections 2.3–2.4: switching between tablet products and from OZEMPIC injection). DailyMed (NLM), SetID 27f15fac-7d98-4114-a2ec-92494a91da98. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  8. 8.Aronne LJ, Horn DB, le Roux CW, Chao AM, Ho W, Halpern B, Griffin R, Xie C, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026. PMID: 42120723.
  9. 9.Novo Nordisk Inc. OZEMPIC (semaglutide) injection — US Prescribing Information. DailyMed (NLM), SetID adec4fd2-6858-4c99-91d4-531f5f2a2d79. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  10. 10.Eli Lilly and Company. Foundayo (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S. (press release, April 9, 2026). Eli Lilly and Company via BioSpace. 2026. https://www.biospace.com/press-releases/foundayo-orforglipron-lillys-new-oral-glp-1-pill-for-weight-loss-now-available-in-the-u-s
  11. 11.Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021. PMID: 34170647.
  12. 12.Aronne LJ, Horn DB, le Roux CW, et al.; SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. PMID: 40353578.

Related research and tools

For the brand-name cheat sheet that disambiguates which product equals which molecule, see our brand cheat sheet. For the plateau diagnosis flow that determines whether you should actually switch, see our plateau guide. For the unit-vs-mg conversion when switching from pens to compounded vials (or back), use our unit converter. For the expected week-by-week curve on each drug, use our weight loss calculator. For the injection technique that stays the same across all switches, see our injection guide. For the specific Wegovy ↔ Zepbound switch question — including the verbatim §2 dose ranges of both DailyMed labels, the SURMOUNT-5 head-to-head efficacy + safety data (the head-to-head obesity trial), the cross-trial caveats from STEP-1 vs SURMOUNT-1, the re-titration logic in either direction, and the CVS Caremark July 2025 formulary swap that drove most current switch volume — see our Wegovy ↔ Zepbound switch dose-equivalence guide.

Further reading

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Read full review →

Pricing Compare

Get started →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Read full review →

Pricing Compare

Get started →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

Pricing Compare

Get started →